复星医药(600196.SH):禅城医院及复星医疗拟向豫园股份转让佛山禅曦100%股权及相关债权
格隆汇 4 月 26日丨复星医药(600196.SH)公布,为聚焦主业,控股子公司禅城医院及复星医疗拟向豫园股份转让所持有的佛山禅曦合计100%的股权以及截至2020年12月31日因股东借款而形成的对佛山禅曦的债权,此次转让总价为人民币5.5亿元,其中:股权转让价款人民币17611.28万元、债权转让价款人民币37388.72万元。
同时,佛山禅曦与禅城医院将继续履行2020年1月签订的《定制协议》,由佛山禅曦为禅城医院定制建设用于运营妇女儿童医学中心、养护院的相关物业(即“禅医健康城综合体项目”中的第5座住院楼和第6座养护院,以下合称“定制工程”),于该等定制工程完成竣工验收备案后及时交付禅城医院使用,并以资产转让的方式将定制工程的产权办理至禅城医院名下。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.